Physician profile
Emilyn Powell
NPI 1205604261
$525.70
in general payments reported to CMS, 2019-2025
14 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $203 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $132.34 | 2024-2025 | |
| Amgen INC. | $82.04 | 2024-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $53.95 | 2025 | Amvuttra |
| Novo Nordisk INC | $48.49 | 2025 | Wegovy |
| Abbott Laboratories | $31.40 | 2025 | Jot Dx |
| Boston Scientific Corporation | $27.07 | 2025 | Watchman Flx |
| Organogenesis INC. | $23.31 | 2025 | Puraply Wound Matrix |
| Atricure, INC. | $19.84 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.06 | 2025 | Uptravi, Opsynvi |
| Kestra Medical Technology Services, INC. | $19.03 | 2025 | Assure Wcd |
| Pfizer INC. | $18.93 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $17.46 | 2024 | Farxiga |
| Scpharmaceuticals INC. | $17.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilyn Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.